Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
4312 participants
OBSERVATIONAL
2025-06-12
2028-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Lung cancer incidence is strongly correlated with socioeconomic status, yet underserved populations remain difficult to engage in screening programs. Mobile health units using a "reach-out" strategy have demonstrated effectiveness in other countries (UK, Brazil, USA). In France, this approach has been used for breast cancer screening via mobile mammography units.
The MobILYAD project aims to compare two screening modalities- a mobile demedicalized unit (CT-equipped van with trained nurses) and a conventional hospital-based unit- to assess the effectiveness of mobile screening in reaching socially disadvantaged populations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Experimentation With Screening for Bronchopulmonary Cancer and Primary Cardiovascular Prevention, Early Management of COPD and an Offer Exempted From Smoking Cessation
NCT05440123
DEPRECAP: Lung Cancer Screening Programme by LDCT for Patients With COPD or Emphysema.
NCT06690385
Lung Cancer Screening by Low Dose CT Scan in a French Department (DEP KP80)
NCT03853967
Incident Chronic Obstructive pulmoNary dIsease Cohort Study (ICONIC)
NCT04252781
Systematic Screening for COPD in Tabacology Consultation
NCT04843605
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mobile Screening Group
Participants receiving lung cancer screening via a mobile unit (truck) operated by trained nurses. This includes spirometry, blood pressure measurement, blood cholesterol testing, low-dose CT scan, and optional biospecimen collection.
Low-dose Chest CT Screening
Participants undergo a low-dose chest CT scan to screen for early lung cancer and assess associated conditions (emphysema, coronary calcifications, osteoporosis).
Spirometry
Assessment of lung function through spirometry, with optional plethysmography and diffusion testing to detect COPD and PRISM patterns.
Cardiovascular Risk Assessment
Cardiovascular risk is evaluated using SCORE2/SCORE2-OP tools, based on blood pressure and cholesterol levels.
Smoking Cessation Support
Active smokers receive a structured smoking cessation intervention, including a baseline consultation and up to two follow-up sessions (which may be remote).
Optional Biospecimen Collection (Bio-ILYAD)
Optional collection of blood and exhaled breath condensate for future analysis of biomarkers in lung cancer detection.
Non-Mobile Screening Group
Participants receiving the same screening procedures at a fixed hospital-based site (Lyon Sud), with possible involvement of medical or non-medical staff depending on availability.
Low-dose Chest CT Screening
Participants undergo a low-dose chest CT scan to screen for early lung cancer and assess associated conditions (emphysema, coronary calcifications, osteoporosis).
Spirometry
Assessment of lung function through spirometry, with optional plethysmography and diffusion testing to detect COPD and PRISM patterns.
Cardiovascular Risk Assessment
Cardiovascular risk is evaluated using SCORE2/SCORE2-OP tools, based on blood pressure and cholesterol levels.
Smoking Cessation Support
Active smokers receive a structured smoking cessation intervention, including a baseline consultation and up to two follow-up sessions (which may be remote).
Optional Biospecimen Collection (Bio-ILYAD)
Optional collection of blood and exhaled breath condensate for future analysis of biomarkers in lung cancer detection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low-dose Chest CT Screening
Participants undergo a low-dose chest CT scan to screen for early lung cancer and assess associated conditions (emphysema, coronary calcifications, osteoporosis).
Spirometry
Assessment of lung function through spirometry, with optional plethysmography and diffusion testing to detect COPD and PRISM patterns.
Cardiovascular Risk Assessment
Cardiovascular risk is evaluated using SCORE2/SCORE2-OP tools, based on blood pressure and cholesterol levels.
Smoking Cessation Support
Active smokers receive a structured smoking cessation intervention, including a baseline consultation and up to two follow-up sessions (which may be remote).
Optional Biospecimen Collection (Bio-ILYAD)
Optional collection of blood and exhaled breath condensate for future analysis of biomarkers in lung cancer detection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Active smokers or former smokers who quit less than 15 years ago.
* Persons whose consumption is estimated at 20 packs/year or more, down to ≥15 cigarettes/day for a duration of consumption of ≥25 years and up to ≥10 cigarettes/day for ≥30 years, which takes into account the predominance of duration of consumption over quantity consumed in the risk of lung cancer. A pack-year corresponds to the consumption of one pack of 20 manufactured cigarettes per day for one year. A multiplier coefficient will be taken into account depending on the mode of consumption: Rolled cigarettes: 2; Cigarillos: 3; Cigars: 4; Pipes: 2.5; Hookahs: 25.
* Persons affiliated with social security. - Person having signed their consent to participate in the study after having received full information about it, including the risks associated with participation.
Exclusion Criteria
* Individuals with impaired general condition (PS 2 and above);
* Individuals with dyspnea at rest (mMRC4);
* Individuals with a history of cancer undergoing active surveillance by chest computed tomography (CT or PET scan); personal history of lung cancer (lifetime);
* Individuals with symptoms suggestive of lung cancer (hemoptysis, unexplained weight loss, recent onset or change in respiratory symptoms, etc.);
* Individuals refusing to participate in the study
* Individuals withdrawing their consent.
50 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
" Centre de dépistage mobile " - Hôpital Lyon Sud
Pierre-Bénite, , France
Service de Pneumologie " Centre de dépistage non mobile " - Hôpital Lyon Sud
Pierre-Bénite, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-A00673-46
Identifier Type: OTHER
Identifier Source: secondary_id
69HCL22_0467
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.